Bayer’s $181 Million Patent Win Over Adynovate Upheld

Bayer HealthCare LLC won a Federal Circuit decision upholding its $181 million patent infringement win over Baxalta Inc.’s biologic drug Adynovate.

The U.S. Court of Appeals for the Federal Circuit said there was substantial evidence supporting a jury’s finding that Adynovate infringes Bayer’s U.S. Patent No. 9,364,520. The drug is used to treat hemophilia A, a genetic disorder that causes blood not to clot normally.

The jury awarded Bayer $155 million as a reasonable royalty for Baxalta’s sales through November 2018. Following the Feb. 4, 2019, verdict, the district court added an additional $18.3 million in supplemental damages, along ...